Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.43 |
| ▸ | MDM4 | O15151 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20825662 | 0.86 | MDM4 (0.48) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL178780 | 0.86 | MDM4 (0.48) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL29399489 | 0.86 | MDM4 (0.48) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL1405653 | 0.86 | MDM4 (0.48) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL178788 | 0.86 | MDM4 (0.48) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL13697519 | 0.86 | MDM4 (0.48) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL29398335 | 0.86 | MDM4 (0.48) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL10231780 | 0.86 | MDM4 (0.48) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL178777 | 0.84 | CASP3 (0.49) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL17256393 | 0.84 | CASP3 (0.49) | CASP3MDM4TP53KMT2ATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528922-B1 | POLYHETEROCYCLIC COMPOUNDS AS HCV INHIBITORS | AB PHARMA LTD (CN) | 2017-08-02 | — | — | EP | disclosed |
| WO-2011091757-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | AB Pharma Ltd. (CN) | 2011-08-04 | — | — | WO | disclosed |
| US-20110183895-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | AB Pharma Ltd. (CN) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183895-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | HAVCR2, ZC3HAV1, EIF2AK2 | CASP3 2349/4885MDM4 4184/4885TP53 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.